恒瑞医药：HRS-7172片、注射用SHR-A2009获批临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new type of anti-tumor small molecule inhibitor, with no similar drugs approved for market domestically or internationally [1] Group 1 - The company has developed HRS-7172 tablets, which are a novel anti-tumor small molecule inhibitor [1] - The approval for HRS-7172 marks a significant milestone as there are currently no similar drugs available in the market [1] Group 2 - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical, has also received approval for clinical trials of SHR-A2009 injection, an antibody-drug conjugate targeting HER3 [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and release of cytotoxic agents within the cells [1] - There are no similar drugs approved globally for SHR-A2009, indicating a unique position in the market [1]